Anixa Biosciences, Inc.

NasdaqCM:ANIX Voorraadrapport

Marktkapitalisatie: US$106.8m

Anixa Biosciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Anixa Biosciences heeft een totaal eigen vermogen van $20.7M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $22.9M en $2.2M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$20.75m
AandelenUS$20.69m
Totaal verplichtingenUS$2.22m
Totaal activaUS$22.91m

Recente financiële gezondheidsupdates

Recent updates

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Sep 12
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

May 23
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

Jan 19
We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Oct 06
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Apr 27
Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Jan 13
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Sep 26
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Aug 15

Anixa to get additional US patent linked to breast cancer vaccine technology

Jul 21

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jun 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

May 11

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Feb 24
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Oct 28
Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Our First Look At Anixa Biosciences

Sep 23

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

Jun 12
Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

OntoChem assigns Anixa covid-19 drug discovery project to MolGenie

May 07

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jan 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact

Dec 01

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $22.7M ) ANIX } overtreffen de korte termijn passiva ( $2.0M ).

Langlopende schulden: De kortetermijnactiva ANIX ( $22.7M ) overtreffen de langetermijnschulden ( $213.0K ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ANIX is schuldenvrij.

Schuld verminderen: ANIX had 5 jaar geleden geen schulden.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: ANIX heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: ANIX heeft voldoende kasruimte voor 1.4 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 7.8 % per jaar.


Ontdek gezonde bedrijven